Lenabdor

Lenalidomide, the active ingredient in Lenabdor, is a immunomodulatory drug (IMiD) presented as an oral formulation for systemic use. It is indicated for the treatment of certain blood cancers, including multiple myeloma, mantle cell lymphoma, and myelodysplastic syndromes, and is prescribed for adult patients under specialist supervision.

GNH USA supplies Lenabdor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with distribution originating from the European Union market.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies and related disorders.

Multiple myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease. Mantle cell lymphoma: contributes to disease control in patients who have received prior therapies. Myelodysplastic syndromes: reduces transfusion dependence and may improve blood counts in patients with lower‑risk disease.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue or weakness - Nausea or vomiting - Diarrhea or constipation - Rash or pruritus - Decreased neutrophil count (neutropenia) - Anemia

Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism - Severe neutropenia or leukopenia leading to infection - Secondary primary malignancies - Hepatotoxicity (elevated liver enzymes) - Severe cutaneous reactions such as Stevens‑Johnson syndrome

Before initiating therapy, clinicians should assess baseline laboratory values and patient risk factors.

Pregnancy risk: Lenalidomide is contraindicated in pregnancy; ensure effective contraception for both patient and partner. Thromboembolic risk: Evaluate need for prophylactic anticoagulation in patients with additional risk factors. Renal function: Adjust monitoring in patients with impaired renal clearance. Infection monitoring: Observe for signs of infection due to neutropenia. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Lenalidomide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) that may reduce exposure. - Thalidomide or other teratogenic agents that increase fetal risk. - Live vaccines, which may cause uncontrolled infection.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, DOACs) – increased bleeding risk. - CYP3A4 inhibitors (ketoconazole, erythromycin) – may raise lenalidomide levels. - Immunosuppressants (cyclosporine, tacrolimus) – heightened infection susceptibility.